Intralesional Methotrexate: A Cost-Effective, High-Efficacy Alternative to Surgery for Cutaneous Squamous Cell Carcinoma
Abstract
Squamous cell carcinoma (SCC) is the second most common type of skin cancer and often is treated surgically. Not all patients are surgical candidates, and sometimes the cost of Mohs micrographic surgery or wide local excision is a barrier for patients. In this study, we explored the use of intralesional methotrexate (IL-MTX) as a treatment for SCC. Our results demonstrate that treatment with IL-MTX could be an excellent option for patients who cannot be treated surgically. However, more research is needed to characterize which lesions are the best candidates for IL-MTX therapy.
Fields of Study & Subjects
Nonmelanoma Skin Cancer Studies
Head and Neck Cancer Studies
Cancer and Skin Lesions
Publication details
- Journal / source
- Cutis
- Volume
- 1
- Issue
- 117
- Pages
- E29–E32
- Publication date
- 1 January 2026
- Language
- EN